NDA 011210 · Pfizer
Tessalon
Benzonatate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jan 20, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1958
Feb 10, 1958
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 10, 1958 Original approval · Type 1 - New Molecular Entity
2 products under this application
- TESSALON · BENZONATATE 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
- TESSALON · BENZONATATE 100MG · CAPSULE, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Benzonatate" as an intervention, any sponsor and status, largest first.
- A Study on the Efficacy and Safety of Benzonatate Soft Capsules for Improving Adult Cough SymptomsPivotal-lookingStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT03722914 · 220 participants (planned) · Start Mar 1, 2018 · Primary completion Dec 31, 2018
Drug: Benzonatate 200 mg; blank control 0mg · For: Cough
Sites: Beijing, China; Harbin, China; Zhengzhou, China · 14 sites in all
- Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILDPivotal-lookingNot yet recruiting
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT07859839 · 177 participants (planned) · Start Oct 7, 2026 · Primary completion Jun 30, 2027
Drug: Gabapentin; Benzonatate 200 mg · For: Interstitial Lung Disease
Sites: Chandigarh, India
PfizerPfizer (PFE)
NCT02207699 · 68 participants · Start May 2014 · Primary completion Jul 2014
Drug: Benzonatate 200 mg; Benzonatate 800 mg and 2 more · For: Healthy Volunteers
Sites: Overland Park, Kansas
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT03922373 · 40 participants (planned) · Start Sep 10, 2018 · Primary completion Feb 27, 2019
Drug: Group A: Benzonatate 100mg; Group B: Benzonatate 200mg and 1 more · For: Cough
Sites: Shijiazhuang, China
- Benzonatate Dose Tolerance StudyCompleted
PfizerPfizer (PFE)
NCT01690975 · 9 participants · Start Jul 2012 · Primary completion Aug 2012
Drug: Placebo; Benzonatate - 400 mg and 1 more · For: Cough
Sites: New Haven, Connecticut
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Benzonatate Safety and Effectiveness: A Systematic Review of the Literature.
Costantino RC, Leonard J, Gorman EF, et al. · Ann Pharmacother 2023 · Systematic Review
- A description of the clinical course of severe benzonatate poisonings reported in the literature and to NPDS: A systematic review supplemented with NPDS cases.
Minhaj FS, Leonard JB · Hum Exp Toxicol 2021 · Systematic Review
- Rapid oral anesthesia for awake intubation.
Mongan PD, Culling RD · J Clin Anesth 1992 · Clinical Trial, Comparative Study
- Inhibition of cough-reflex sensitivity by benzonatate and guaifenesin in acute viral cough.
Dicpinigaitis PV, Gayle YE, Solomon G, et al. · Respir Med 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.